---
title: "WECOME: Huangjia Soft Liver Granules initiate Phase III clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/258844207.md"
description: "WECOME and Yingkerui Pharmaceutical Co., Ltd. jointly applied for the Phase III clinical trial of Huangjia Soft Liver Granules. The trial aims to evaluate the efficacy and safety of Huangjia Soft Liver Granules in treating chronic hepatitis B virus-related liver fibrosis. The Phase II trial has been completed, showing good clinical efficacy and safety. This trial will include 480 participants and will adopt a randomized, double-blind, placebo-controlled design"
datetime: "2025-09-25T09:39:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/258844207.md)
  - [en](https://longbridge.com/en/news/258844207.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/258844207.md)
---

# WECOME: Huangjia Soft Liver Granules initiate Phase III clinical trials

According to the Zhitong Finance APP, WECOME (300878.SZ) announced that the company, in collaboration with Yingkerui (Zhuhai Jinwan) Pharmaceutical Co., Ltd., has jointly applied for a project led by the Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, along with 19 clinical trial centers including the First Affiliated Hospital of Anhui Medical University, the Third Gorges Hospital affiliated with Chongqing University, and the First Affiliated Hospital of Chongqing Medical University, to hold a project launch meeting for the "Randomized, Double-Blind, Multi-Center, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Huangjia Soft Liver Granules in Treating Chronic Hepatitis B Virus-Related Liver Fibrosis (Liver Qi Stagnation and Spleen Deficiency with Blood Stasis Obstructing the Channels)."

The announcement stated that the results of the completed Phase II clinical trial showed that Huangjia Soft Liver Granules have good clinical efficacy and safety in treating chronic hepatitis B virus-related liver fibrosis (Liver Qi Stagnation and Spleen Deficiency with Blood Stasis Obstructing the Channels), with clinical benefits for patients exceeding potential risks. This Phase III clinical trial will adopt a randomized, double-blind, placebo-controlled, multi-center clinical trial design, aiming to enroll 480 subjects to confirm the safety and efficacy of Huangjia Soft Liver Granules in treating chronic hepatitis B virus-related liver fibrosis (Liver Qi Stagnation and Spleen Deficiency with Blood Stasis Obstructing the Channels)

### Related Stocks

- [300878.CN](https://longbridge.com/en/quote/300878.CN.md)

## Related News & Research

- [TRUMP: VENEZUELAN OIL COMING TO TEXAS, LOUISIANA AND ALASKA](https://longbridge.com/en/news/287097512.md)
- [Obamacare Meltdown? Sharp ACA Enrollment Drop Expected As Pandemic-Era Subsidies End](https://longbridge.com/en/news/287067300.md)
- [US CDC OFFICIAL SAYS AMERICAN EBOLA PATIENT HAS LANDED IN GERMANY](https://longbridge.com/en/news/287104395.md)
- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [Dunkin' To Give Away 1 Mln Free Coffees For A Day](https://longbridge.com/en/news/286964019.md)